Current studies on the immunotherapy of cervical carcinoma have primarily focused on therapeutic vaccines targeting E6 and E7 oncoproteins11 and checkpoint inhibitors of PD‐1/PD‐L1.12 Here, CD274 is linked to cervical carcinoma.